NCCN guidelines for survivorship expanded to address two common conditions.
The NCCN Clinical Practice Guidelines in Oncology for Survivorship include a new section on cancer-associated cognitive impairment and an expanded section on adult cancer pain that more completely addresses chemotherapy-induced peripheral neuropathy. These additions to the guidelines are the result of increasing awareness that long-term cancer survivors struggle with many late effects. Both the assessment and the management of cognitive impairment still lack a strong evidence-based foundation. The management of peripheral neuropathy, including the use of anti-depressants and opioids, often in combination, is backed by data primarily derived from clinical trials performed for various types of peripheral neuropathy.
Presented by Elizabeth Kvale, MD, Director of Supportive Care and Survivorship, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, and Susan G. Urba, MD, Professor, Medical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
Elizabeth
E
Kvale
Presented by Elizabeth Kvale, MD, Director of Supportive Care and Survivorship, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, and Susan G. Urba, MD, Professor, Medical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
Susan G
SG
Urba
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D060825:Cognitive Dysfunction / Q000209:etiology*; D019468:Disease Management; D006801:Humans; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D017410:Practice Guidelines as Topic; D017741:Survivors